Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | JMJD6 | Q6NYC1 | 2/20 | 0.44 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16247834 | 0.92 | L3MBTL1 (0.40) | MEN1KMT2AJMJD6PDE1CTP53 | |
| SCHEMBL20369182 | 0.90 | JMJD6 (0.47) | MEN1KMT2AJMJD6PDE1CLMNA | |
| SCHEMBL13625641 | 0.86 | PRKCA (0.42) | MEN1KMT2AJMJD6PDE1CLMNA | |
| SCHEMBL18304677 | 0.85 | NPC1 (0.56) | JMJD6PDE1C | |
| SCHEMBL107374 | 0.84 | L3MBTL1 (0.43) | MEN1KMT2ATP53GAAHTR7 | |
| SCHEMBL14882891 | 0.84 | MMP13 (0.51) | MEN1KMT2ATP53SMN1; SMN2PARP15 | |
| SCHEMBL14883166 | 0.82 | RAB9A (0.51) | MEN1KMT2AJMJD6PARP15PARP10 | |
| SCHEMBL6720808 | 0.81 | ESR1 (0.51) | MEN1KMT2AJMJD6PDE1CLMNA | |
| SCHEMBL10087721 | 0.81 | LCK (0.43) | MEN1KMT2AJMJD6PDE1CLMNA | |
| SCHEMBL3468807 | 0.81 | PARP15 (0.54) | MEN1KMT2AJMJD6LMNAPARP15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240219830-A1 | SALT, ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2024-07-04 | — | — | US | disclosed |
| US-20240210824-A1 | CARBOXYLATE, CARBOXYLIC ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2024-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240210824-A1 | CARBOXYLATE, CARBOXYLIC ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | SCO2, CBR1, OXGR1 | MEN1 2790/4885KMT2A 2023/4885JMJD6 1197/4885 |
| US-20240219830-A1 | SALT, ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | H1-0, HCN3, RER1 | MEN1 1558/4885KMT2A 1382/4885JMJD6 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.